SCHEMBL5982951

SCHEMBL5982951

CSc1ncc2[nH]c(=O)n([C@@H]3C[C@@H](O)[C@H](CO)O3)c2n1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TK1 P04183 3/20 0.42
▸ LMNA P02545 2/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ ADRB1 P08588 1/20 0.42
▸ DNMT1 P26358 1/20 0.42
▸ HIF1A Q16665 1/20 0.41
▸ TK2 O00142 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ PKM P14618 1/20 0.41
▸ ALOX12 P18054 1/20 0.40
▸ ADRA1A P35348 1/20 0.40
▸ ADORA3 P0DMS8 1/20 0.40
▸ ADORA2A P29274 1/20 0.40
▸ CYP1A2 P05177 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ BLM P54132 1/20 0.39
▸ PMP22 Q01453 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5982958 1.00 TK1 (0.42) TK1LMNASMN1; SMN2ADRB1DNMT1
SCHEMBL5982339 0.84 ADRB1 (0.55) TK1LMNASMN1; SMN2ADRB1DNMT1
SCHEMBL5982327 0.84 ADRB1 (0.55) TK1LMNASMN1; SMN2ADRB1DNMT1
SCHEMBL5982572 0.84 LMNA (0.49) TK1LMNASMN1; SMN2ADRB1DNMT1
SCHEMBL5982319 0.84 LMNA (0.47) TK1LMNASMN1; SMN2ADRB1DNMT1
SCHEMBL5982567 0.84 LMNA (0.49) TK1LMNASMN1; SMN2ADRB1DNMT1
SCHEMBL5982326 0.84 LMNA (0.47) TK1LMNASMN1; SMN2ADRB1DNMT1
SCHEMBL5983021 0.84 TK1 (0.42) TK1LMNASMN1; SMN2ADRB1DNMT1
SCHEMBL5983165 0.84 TK1 (0.42) TK1LMNASMN1; SMN2ADRB1DNMT1
SCHEMBL5983152 0.84 TK1 (0.42) TK1LMNASMN1; SMN2ADRB1DNMT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1634888-A2 Synthesis of 2'-deoxy-L-nucleosides Pharmasset Limited (US) 2006-03-15 — — EP disclosed
EP-1600452-A2 Synthesis of 2'-deoxy-L-nucleosides Pharmasset Limited (US) 2005-11-30 — — EP disclosed
EP-1600451-A2 Synthesis of 2'-deoxy-l-nucleosides Pharmasset Limited (US) 2005-11-30 — — EP disclosed
US-20050090660-A1 2'-deoxy-L-nucleosides PHARMASSET, INC. 2005-04-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090660-A1 2'-deoxy-L-nucleosides CCNH, ADAR, NSUN2 TK1 661/4885LMNA 845/4885SMN1; SMN2 2345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback